Argonaut Private Equity is a diversified global private equity fund dedicated to building emerging market leaders.
With more than $2 billion under management provided by a single entrepreneur, Argonaut is uniquely positioned to assist entrepreneurial companies. Unlike conventional private equity firms, Argonaut exercises wide discretion on investment size, stage, sector and geography.
Because of its focused ownership and management, Argonaut can make quick decisions without fund restrictions on subsequent investments or exit timing. Its equity investments range from $1 million to $200 million and span such diverse markets as consumer electronics, specialty materials, telecommunications, software, aviation, and healthcare technology and services. Argonaut’s portfolio includes investments in the United States, Israel, India, China, the Netherlands, South Korea and Australia.
| Company | Date | Round | Size | Participants |
| Crown Bioscience | 5/11 | Series C | $28.8M | 4 |
| Yulex | 3/11 | Venture Round | $15M | 1 |
| Aspen Aerogels | 10/10 | Venture Round | $21.5M | 6 |
| eYantra Industries | 7/10 | Venture Round | $7.5M | 1 |
| Luminus Devices | 2/10 | Series B | $18.8M | 4 |
| Amimon | 8/06 | Series B | $14M | 5 |
| TransPharma Medical | 7/06 | Series C | $18M | 7 |
| Flash Networks | 6/06 | Series F | C$15M | 8 |
| Luminus Devices | 5/06 | Series D | $38M | 6 |
| Novariant | 5/05 | Series C | $16M | 7 |
